|
US9045518B2
(en)
|
2002-11-18 |
2015-06-02 |
Santaris Pharma A/S |
Amino-LNA, thio-LNA and alpha-L-oxy-LN
|
|
MX2011004097A
(es)
|
2008-10-15 |
2011-07-28 |
Isis Pharmaceuticals Inc |
Modulacion de la expresion del factor 11.
|
|
RU2572826C2
(ru)
|
2008-12-02 |
2016-01-20 |
Чиралджен, Лтд. |
Способ синтеза модифицированных по атому фосфора нуклеиновых кислот
|
|
CA2767253A1
(en)
|
2009-07-06 |
2011-01-13 |
Ontorii, Inc. |
Novel nucleic acid prodrugs and methods of use thereof
|
|
JP5868324B2
(ja)
|
2010-09-24 |
2016-02-24 |
株式会社Wave Life Sciences Japan |
不斉補助基
|
|
CA3077910A1
(en)
|
2010-11-17 |
2012-05-24 |
Ionis Pharmaceuticals, Inc. |
Modulation of alpha synuclein expression
|
|
AU2012284265B2
(en)
|
2011-07-19 |
2017-08-17 |
Wave Life Sciences Ltd. |
Methods for the synthesis of functionalized nucleic acids
|
|
HK1200484A1
(zh)
|
2011-09-14 |
2015-08-07 |
Translate Bio Ma, Inc. |
多聚寡核苷酸化合物
|
|
US10837014B2
(en)
|
2012-05-16 |
2020-11-17 |
Translate Bio Ma, Inc. |
Compositions and methods for modulating SMN gene family expression
|
|
CA2873769A1
(en)
|
2012-05-16 |
2013-11-21 |
Rana Therapeutics Inc. |
Compositions and methods for modulating hemoglobin gene family expression
|
|
BR112014028634A2
(pt)
|
2012-05-16 |
2017-06-27 |
Rana Therapeutics Inc |
composições e métodos para modulação da expressão de utrn
|
|
CA2873766A1
(en)
|
2012-05-16 |
2013-11-21 |
Rana Therapeutics Inc. |
Compositions and methods for modulating atp2a2 expression
|
|
JP2015523854A
(ja)
|
2012-05-16 |
2015-08-20 |
ラナ セラピューティクス インコーポレイテッド |
Ｓｍｎ遺伝子ファミリー発現を調節するための組成物及び方法
|
|
AU2013262709A1
(en)
|
2012-05-16 |
2015-01-22 |
Rana Therapeutics, Inc. |
Compositions and methods for modulating MECP2 expression
|
|
JP6453212B2
(ja)
|
2012-07-13 |
2019-01-16 |
ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． |
キラル制御
|
|
SG11201500239VA
(en)
|
2012-07-13 |
2015-03-30 |
Wave Life Sciences Japan |
Asymmetric auxiliary group
|
|
EP2895200B1
(en)
|
2012-09-14 |
2019-11-06 |
Translate Bio MA, Inc. |
Multimeric oligonucleotide compounds
|
|
US10077443B2
(en)
|
2012-11-15 |
2018-09-18 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotide conjugates
|
|
CN104955952A
(zh)
*
|
2013-01-30 |
2015-09-30 |
弗·哈夫曼-拉罗切有限公司 |
Lna寡核苷酸碳水化合物缀合物
|
|
SG11201508925WA
(en)
|
2013-05-01 |
2015-11-27 |
Regulus Therapeutics Inc |
Microrna compounds and methods for modulating mir-122
|
|
CN105164261B
(zh)
|
2013-05-01 |
2022-03-18 |
莱古路斯治疗法股份有限公司 |
用于增强的细胞摄取的化合物和方法
|
|
DK2991656T3
(da)
|
2013-05-01 |
2020-03-23 |
Ionis Pharmaceuticals Inc |
Sammensætninger og fremgangsmåder til modulering af apolipoprotein c-iii-ekspression
|
|
WO2015042447A1
(en)
|
2013-09-20 |
2015-03-26 |
Isis Pharmaceuticals, Inc. |
Targeted therapeutic nucleosides and their use
|
|
US11162096B2
(en)
|
2013-10-14 |
2021-11-02 |
Ionis Pharmaceuticals, Inc |
Methods for modulating expression of C9ORF72 antisense transcript
|
|
US9994846B2
(en)
|
2013-10-25 |
2018-06-12 |
Regulus Therapeutics Inc. |
MicroRNA compounds and methods for modulating miR-21 activity
|
|
WO2015108047A1
(ja)
|
2014-01-15 |
2015-07-23 |
株式会社新日本科学 |
免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤
|
|
WO2015108048A1
(ja)
|
2014-01-15 |
2015-07-23 |
株式会社新日本科学 |
抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
|
|
ES2917473T3
(es)
|
2014-01-16 |
2022-07-08 |
Wave Life Sciences Ltd |
Diseño quiral
|
|
WO2015113922A1
(en)
*
|
2014-01-30 |
2015-08-06 |
Roche Innovation Center Copenhagen A/S |
Poly oligomer compound with biocleavable conjugates
|
|
WO2015143245A1
(en)
|
2014-03-19 |
2015-09-24 |
Isis Pharmaceuticals, Inc. |
Methods for modulating ataxin 2 expression
|
|
CN106103717A
(zh)
|
2014-03-19 |
2016-11-09 |
Ionis制药公司 |
用于调节共济失调蛋白2表达的组合物
|
|
RS60707B1
(sr)
|
2014-04-01 |
2020-09-30 |
Biogen Ma Inc |
Kompozicije za modulaciju ekspresije sod-1
|
|
CN110903337A
(zh)
|
2014-05-01 |
2020-03-24 |
Ionis制药公司 |
用于调节生长激素受体表达的组合物和方法
|
|
PT3137605T
(pt)
|
2014-05-01 |
2020-12-18 |
Ionis Pharmaceuticals Inc |
Composições e métodos para modulação da expressão de angiopoietina de tipo 3
|
|
EP3862362A3
(en)
|
2014-05-01 |
2021-10-27 |
Ionis Pharmaceuticals, Inc. |
Conjugates of modified antisense oligonucleotides and their use for modulating pkk expression
|
|
SG11201608502TA
(en)
|
2014-05-01 |
2016-11-29 |
Ionis Pharmaceuticals Inc |
Compositions and methods for modulating complement factor b expression
|
|
GB201408623D0
(en)
|
2014-05-15 |
2014-07-02 |
Santaris Pharma As |
Oligomers and oligomer conjugates
|
|
TW201613949A
(en)
|
2014-08-07 |
2016-04-16 |
Regulus Therapeutics Inc |
Targeting microRNAs for metabolic disorders
|
|
BR112017004056A2
(pt)
|
2014-09-12 |
2017-12-05 |
Biogen Ma Inc |
composições e métodos para detecção da proteína smn em um indivíduo e tratamento de um indivíduo
|
|
WO2016055601A1
(en)
|
2014-10-10 |
2016-04-14 |
F. Hoffmann-La Roche Ag |
Galnac phosphoramidites, nucleic acid conjugates thereof and their use
|
|
PE20170922A1
(es)
*
|
2014-11-10 |
2017-07-12 |
Glaxosmithkline Intellectual Property (No 2) Ltd |
Composiciones de accion prolongada de combinacion y procedimientos para hepatitis c
|
|
CN107208092B
(zh)
|
2014-12-16 |
2021-09-10 |
罗氏创新中心哥本哈根有限公司 |
手性毒性筛选方法
|
|
CA2970795A1
(en)
|
2014-12-18 |
2016-06-23 |
Alnylam Pharmaceuticals, Inc. |
Reversir compounds
|
|
WO2016112132A1
(en)
|
2015-01-06 |
2016-07-14 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of c9orf72 antisense transcript
|
|
US10538763B2
(en)
|
2015-01-16 |
2020-01-21 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulation of DUX4
|
|
WO2016130943A1
(en)
*
|
2015-02-13 |
2016-08-18 |
Rana Therapeutics, Inc. |
Hybrid oligonucleotides and uses thereof
|
|
US11129844B2
(en)
|
2015-03-03 |
2021-09-28 |
Ionis Pharmaceuticals, Inc. |
Compositions and methods for modulating MECP2 expression
|
|
PT3277815T
(pt)
|
2015-04-03 |
2021-11-11 |
Beth Israel Deaconess Medical Ct Inc |
Compostos de oligonucleótidos para o tratamento de pré-eclâmpsia e outros distúrbios angiogénicos
|
|
MX2017012426A
(es)
|
2015-04-03 |
2018-01-26 |
Ionis Pharmaceuticals Inc |
Composiciones y metodos para modular la expresion de tmprss6.
|
|
EP3277811B1
(en)
|
2015-04-03 |
2020-12-23 |
University of Massachusetts |
Fully stabilized asymmetric sirna
|
|
SMT202000454T1
(it)
|
2015-04-03 |
2020-11-10 |
Univ Massachusetts |
Cmposti oligonucleotidici per bersagliare l'mrn della huntingtina
|
|
WO2016167780A1
(en)
|
2015-04-16 |
2016-10-20 |
Ionis Pharmaceuticals, Inc. |
Compositions for modulating expression of c9orf72 antisense transcript
|
|
US10633653B2
(en)
|
2015-08-14 |
2020-04-28 |
University Of Massachusetts |
Bioactive conjugates for oligonucleotide delivery
|
|
JP6835826B2
(ja)
*
|
2015-08-24 |
2021-02-24 |
ロシュ イノベーション センター コペンハーゲン エーエス |
Ｌｎａ−ｇプロセス
|
|
US20210052631A1
(en)
*
|
2015-09-25 |
2021-02-25 |
Ionis Pharmaceuticals, Inc. |
Conjugated antisense compounds and their use
|
|
US10577388B2
(en)
|
2015-10-02 |
2020-03-03 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotide conjugation process
|
|
JP7511326B2
(ja)
|
2015-10-09 |
2024-07-05 |
ウェイブ ライフ サイエンシズ リミテッド |
オリゴヌクレオチド組成物およびその方法
|
|
WO2017068087A1
(en)
|
2015-10-22 |
2017-04-27 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotide detection method
|
|
US20190046555A1
(en)
*
|
2015-11-06 |
2019-02-14 |
Ionis Pharmaceuticals, Inc. |
Conjugated antisense compounds for use in therapy
|
|
AU2016349625B2
(en)
|
2015-11-06 |
2022-07-07 |
Ionis Pharmaceuticals, Inc. |
Modulating apolipoprotein (a) expression
|
|
HUE067905T2
(hu)
|
2015-11-12 |
2024-11-28 |
Hoffmann La Roche |
Oligonukleotidok paternális UBE3A expresszió indukálására
|
|
US11058709B1
(en)
|
2015-12-04 |
2021-07-13 |
Ionis Pharmaceuticals, Inc. |
Methods of treating breast cancer
|
|
US20190002887A1
(en)
|
2015-12-31 |
2019-01-03 |
Ionis Pharmaceuticals, Inc. |
Methods for reducing ataxin-2 expression
|
|
CA3006599A1
(en)
|
2016-01-05 |
2017-07-13 |
Ionis Pharmaceuticals, Inc. |
Methods for reducing lrrk2 expression
|
|
AU2017213404A1
(en)
*
|
2016-01-29 |
2018-09-20 |
Kyowa Kirin Co., Ltd. |
Nucleic acid conjugate
|
|
WO2017132669A1
(en)
|
2016-01-31 |
2017-08-03 |
University Of Massachusetts |
Branched oligonucleotides
|
|
KR102515329B1
(ko)
|
2016-03-07 |
2023-03-29 |
애로우헤드 파마슈티컬스 인코포레이티드 |
치료용 화합물을 위한 표적화 리간드
|
|
KR20250065735A
(ko)
|
2016-03-14 |
2025-05-13 |
에프. 호프만-라 로슈 아게 |
Pd-l1 발현의 감소를 위한 올리고뉴클레오티드
|
|
AU2017234678A1
(en)
|
2016-03-16 |
2018-08-16 |
Ionis Pharmaceuticals, Inc. |
Methods of modulating KEAP1
|
|
WO2017161168A1
(en)
|
2016-03-16 |
2017-09-21 |
Ionis Pharmaceuticals, Inc. |
Modulation of dyrk1b expression
|
|
JP2019513371A
(ja)
|
2016-04-01 |
2019-05-30 |
アビディティー バイオサイエンシーズ エルエルシー |
核酸ポリペプチド組成物とその使用
|
|
EP3228326A1
(en)
*
|
2016-04-05 |
2017-10-11 |
Silence Therapeutics GmbH |
Nucleic acid linked to a trivalent glycoconjugate
|
|
WO2017177169A1
(en)
*
|
2016-04-08 |
2017-10-12 |
Rana Therapeutics, Inc. |
Multimeric coding nucleic acid and uses thereof
|
|
EP3442983A1
(en)
|
2016-04-14 |
2019-02-20 |
H. Hoffnabb-La Roche Ag |
TRITYL-MONO-Ga1NAc COMPOUNDS AND THEIR USE
|
|
JP7091255B2
(ja)
*
|
2016-05-06 |
2022-06-27 |
アイオニス・ファーマシューティカルズ・インコーポレイテッド |
Ｇｌｐ－１受容体リガンド部分コンジュゲート化オリゴヌクレオチドおよびその使用
|
|
EP3471781A4
(en)
|
2016-06-17 |
2020-05-06 |
Ionis Pharmaceuticals, Inc. |
MODULATION OF GYS1 EXPRESSION
|
|
CN109414448B
(zh)
|
2016-06-17 |
2021-10-26 |
豪夫迈·罗氏有限公司 |
用于减少PAPD5或PAPD7 mRNA治疗乙型肝炎感染的核酸分子
|
|
EP3475424A1
(en)
|
2016-06-22 |
2019-05-01 |
ProQR Therapeutics II B.V. |
Single-stranded rna-editing oligonucleotides
|
|
AU2017289204A1
(en)
|
2016-07-01 |
2019-01-17 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides for modulating HTRA1 expression
|
|
CA3033368A1
(en)
|
2016-08-12 |
2018-02-15 |
University Of Massachusetts |
Conjugated oligonucleotides
|
|
US10941402B2
(en)
|
2016-09-01 |
2021-03-09 |
Proqr Therapeutics Ii B.V. |
Chemically modified single-stranded RNA-editing oligonucleotides
|
|
MX2018009853A
(es)
|
2016-09-02 |
2018-11-09 |
Arrowhead Pharmaceuticals Inc |
Ligandos de direccion.
|
|
EP3522898A4
(en)
|
2016-10-06 |
2020-05-27 |
Ionis Pharmaceuticals, Inc. |
METHOD FOR CONJUGATING OLIGOMERIC COMPOUNDS
|
|
JOP20190104A1
(ar)
|
2016-11-10 |
2019-05-07 |
Ionis Pharmaceuticals Inc |
مركبات وطرق لتقليل التعبير عن atxn3
|
|
WO2018102745A1
(en)
|
2016-12-02 |
2018-06-07 |
Cold Spring Harbor Laboratory |
Modulation of lnc05 expression
|
|
WO2018130582A1
(en)
|
2017-01-13 |
2018-07-19 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating rel expression
|
|
US20190367920A1
(en)
|
2017-01-13 |
2019-12-05 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating nfkb1 expression
|
|
WO2018130585A1
(en)
|
2017-01-13 |
2018-07-19 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating relb expression
|
|
US20190345495A1
(en)
|
2017-01-13 |
2019-11-14 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating nfkb2 expression
|
|
US20200216845A1
(en)
|
2017-01-13 |
2020-07-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides for modulating rela expression
|
|
US11963974B2
(en)
|
2017-03-10 |
2024-04-23 |
National Center For Child Health And Development |
Antisense oligonucleotide and composition for prevention or treatment of glycogen storage disease type Ia
|
|
WO2018165541A1
(en)
*
|
2017-03-10 |
2018-09-13 |
The Board Of Regents Of The University Of Texas System |
Treatment of fuchs' endothelial corneal dystrophy
|
|
WO2018191278A2
(en)
*
|
2017-04-11 |
2018-10-18 |
Arbutus Biopharma Corporation |
Targeted compositions
|
|
WO2018215049A1
(en)
|
2017-05-23 |
2018-11-29 |
F. Hoffmann-La Roche Ag |
Process for galnac oligonucleotide conjugates
|
|
US11273222B2
(en)
|
2017-05-26 |
2022-03-15 |
National Cerebral And Cardiovascular Center |
Antisense nucleic acid targeting PCSK9
|
|
US20190055564A1
(en)
|
2017-06-01 |
2019-02-21 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides for modulating htra1 expression
|
|
JP2020522265A
(ja)
*
|
2017-06-02 |
2020-07-30 |
ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． |
オリゴヌクレオチド組成物及びその使用方法
|
|
WO2018226788A1
(en)
|
2017-06-07 |
2018-12-13 |
University Of Massachusetts |
Anti-adam33 oligonucleotides and related methods
|
|
JP7406793B2
(ja)
|
2017-06-23 |
2023-12-28 |
ユニバーシティー オブ マサチューセッツ |
２テイル自己デリバリー型ｓｉＲＮＡおよび関連方法
|
|
WO2019030574A1
(en)
|
2017-08-10 |
2019-02-14 |
Cerenis Therapeutics Holding |
Cargomers
|
|
WO2019030313A2
(en)
|
2017-08-11 |
2019-02-14 |
Roche Innovation Center Copenhagen A/S |
OLIGONUCLEOTIDES FOR MODULATION OF UBE3C EXPRESSION
|
|
CA3073213A1
(en)
|
2017-08-17 |
2019-02-21 |
Alnylam Pharmaceuticals, Inc. |
Tunable reversir tm compounds
|
|
US11197884B2
(en)
|
2017-08-18 |
2021-12-14 |
Ionis Pharmaceuticals, Inc. |
Modulation of the notch signaling pathway for treatment of respiratory disorders
|
|
WO2019038228A1
(en)
|
2017-08-22 |
2019-02-28 |
Roche Innovation Center Copenhagen A/S |
OLIGONUCLEOTIDES FOR MODULATION OF TOM1 EXPRESSION
|
|
US10517889B2
(en)
|
2017-09-08 |
2019-12-31 |
Ionis Pharmaceuticals, Inc. |
Modulators of SMAD7 expression
|
|
EP3694530A4
(en)
*
|
2017-10-12 |
2021-06-30 |
Wave Life Sciences Ltd. |
COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES
|
|
CN111226114A
(zh)
|
2017-10-13 |
2020-06-02 |
罗氏创新中心哥本哈根有限公司 |
用部分立体限定的寡核苷酸子文库鉴定反义寡核苷酸改进的立体限定硫代磷酸酯寡核苷酸变体的方法
|
|
UA126931C2
(uk)
|
2017-10-16 |
2023-02-22 |
Ф. Хоффманн-Ля Рош Аг |
МОЛЕКУЛИ НУКЛЕЇНОВИХ КИСЛОТ ДЛЯ ЗМЕНШЕННЯ РІВНЯ мРНК PAPD5 І PAPD7 ДЛЯ ЛІКУВАННЯ ІНФЕКЦІЙНОГО ГЕПАТИТУ B
|
|
AU2018359904B2
(en)
|
2017-11-06 |
2023-02-23 |
Nitto Denko Corporation |
Fusogenic compounds for delivery of biologically active molecules
|
|
TWI809004B
(zh)
|
2017-11-09 |
2023-07-21 |
美商Ionis製藥公司 |
用於降低snca表現之化合物及方法
|
|
CA3083968C
(en)
|
2017-12-01 |
2024-04-23 |
Suzhou Ribo Life Science Co., Ltd. |
Double-stranded oligonucleotide, composition and conjugate comprising double-stranded oligonucleotide, preparation method thereof and use thereof
|
|
WO2019105437A1
(zh)
|
2017-12-01 |
2019-06-06 |
苏州瑞博生物技术有限公司 |
一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
|
|
WO2019105435A1
(zh)
|
2017-12-01 |
2019-06-06 |
苏州瑞博生物技术有限公司 |
一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
|
|
CN110945130B
(zh)
|
2017-12-01 |
2024-04-09 |
苏州瑞博生物技术股份有限公司 |
一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
|
|
JP7365052B2
(ja)
|
2017-12-01 |
2023-10-19 |
スーチョウ リボ ライフ サイエンス カンパニー、リミテッド |
核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用
|
|
JP7506601B2
(ja)
|
2017-12-06 |
2024-06-26 |
アビディティー バイオサイエンシーズ，インク． |
筋萎縮症と筋緊張性ジストロフィーを処置するための組成物および方法
|
|
US20200385714A1
(en)
|
2017-12-11 |
2020-12-10 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating fndc3b expression
|
|
WO2019115417A2
(en)
|
2017-12-12 |
2019-06-20 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating rb1 expression
|
|
US11459564B2
(en)
|
2017-12-21 |
2022-10-04 |
Ionis Pharmaceuticals, Inc. |
Modulation of frataxin expression
|
|
JP2021507253A
(ja)
|
2017-12-21 |
2021-02-22 |
エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ |
Ｈｔｒａ１ ｒｎａアンタゴニストについてのコンパニオン診断
|
|
WO2019122282A1
(en)
|
2017-12-22 |
2019-06-27 |
Roche Innovation Center Copenhagen A/S |
Gapmer oligonucleotides comprising a phosphorodithioate internucleoside linkage
|
|
WO2019122279A1
(en)
|
2017-12-22 |
2019-06-27 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides comprising a phosphorodithioate internucleoside linkage
|
|
CN111448316B
(zh)
|
2017-12-22 |
2025-02-14 |
罗氏创新中心哥本哈根有限公司 |
新的硫代亚磷酰胺
|
|
EP3732185B1
(en)
|
2017-12-29 |
2025-02-26 |
Suzhou Ribo Life Science Co., Ltd. |
Conjugates and preparation and use thereof
|
|
US20210095274A1
(en)
|
2018-01-10 |
2021-04-01 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating pias4 expression
|
|
AU2019207859A1
(en)
|
2018-01-12 |
2020-07-02 |
Roche Innovation Center Copenhagen A/S |
Alpha-synuclein antisense oligonucleotides and uses thereof
|
|
US20210095275A1
(en)
|
2018-01-12 |
2021-04-01 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating gsk3b expression
|
|
EA202091693A1
(ru)
|
2018-01-12 |
2021-04-14 |
Бристол-Маерс Сквибб Компани |
Антисмысловые олигонуклеотиды, целенаправленно воздействующие на альфа-синуклеин, и их применения
|
|
BR112020013994A2
(pt)
|
2018-01-12 |
2020-12-08 |
Bristol-Myers Squibb Company |
Oligonucleotídeos antissenso que direcionam alfa-sinucleína e seus usos
|
|
BR112020014425A2
(pt)
|
2018-01-15 |
2020-12-29 |
Ionis Pharmaceuticals, Inc. |
Moduladores de expressão de dnm2
|
|
CN111615558A
(zh)
|
2018-01-17 |
2020-09-01 |
罗氏创新中心哥本哈根有限公司 |
用于调节erc1表达的寡核苷酸
|
|
WO2019141723A1
(en)
|
2018-01-18 |
2019-07-25 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting srebp1
|
|
EP3743116B1
(en)
*
|
2018-01-26 |
2024-07-10 |
F. Hoffmann-La Roche AG |
Radiolabelled oligonucleotides and process for their preparation
|
|
WO2019145386A1
(en)
|
2018-01-26 |
2019-08-01 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating csnk1d expression
|
|
CA3088071A1
(en)
*
|
2018-02-09 |
2019-08-15 |
Genentech, Inc. |
Oligonucleotides for modulating tmem106b expression
|
|
KR20200140805A
(ko)
|
2018-02-21 |
2020-12-16 |
브리스톨-마이어스 스큅 컴퍼니 |
Camk2d 안티센스 올리고뉴클레오티드 및 그의 용도
|
|
EP3759127A4
(en)
|
2018-03-02 |
2022-03-30 |
Ionis Pharmaceuticals, Inc. |
COMPOUNDS AND METHODS FOR MODULATING AMYLOID BETA PRECURSOR PROTEIN
|
|
TWI840345B
(zh)
|
2018-03-02 |
2024-05-01 |
美商Ionis製藥公司 |
Irf4表現之調節劑
|
|
CN111511915A
(zh)
|
2018-03-09 |
2020-08-07 |
第一三共株式会社 |
糖原病Ia型治疗药
|
|
US11661601B2
(en)
|
2018-03-22 |
2023-05-30 |
Ionis Pharmaceuticals, Inc. |
Methods for modulating FMR1 expression
|
|
MA52661A
(fr)
|
2018-04-05 |
2021-02-17 |
Centre Leon Berard |
Utilisation d'inhibiteurs de fubp1 dans le traitement d'une infection par le virus de l'hépatite b
|
|
CA3094020A1
(en)
|
2018-04-11 |
2019-10-17 |
Ionis Pharmaceuticals, Inc. |
Modulators of ezh2 expression
|
|
WO2019215066A1
(en)
|
2018-05-07 |
2019-11-14 |
Roche Innovation Center Copenhagen A/S |
Quality control of lna oligonucleotide therapeutics using massively parallel sequencing
|
|
US20210371860A1
(en)
|
2018-05-08 |
2021-12-02 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides for modulating myh7 expression
|
|
EP3790972A1
(en)
|
2018-05-08 |
2021-03-17 |
Regulus Therapeutics Inc. |
Galnac conjugated modified oligonucleotide as mir-122 inhibitor having hcv antiviral activity with reduced hyperbilirubinemia side-effect
|
|
JP7438135B2
(ja)
|
2018-05-09 |
2024-02-26 |
アイオーニス ファーマシューティカルズ， インコーポレーテッド |
Ｆｘｉの発現を低下させるための化合物及び方法
|
|
SG11202010215TA
(en)
|
2018-05-09 |
2020-11-27 |
Ionis Pharmaceuticals Inc |
Compounds and methods for reducing atxn3 expression
|
|
CA3098266A1
(en)
*
|
2018-05-11 |
2019-11-14 |
Alpha Anomeric Sas |
Oligonucleotides conjugates comprising 7'-5'-alpha-anomeric-bicyclic sugar nucleosides
|
|
EP3790596A4
(en)
|
2018-05-11 |
2022-04-06 |
Wave Life Sciences Ltd. |
OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE
|
|
GB201808146D0
(en)
|
2018-05-18 |
2018-07-11 |
Proqr Therapeutics Ii Bv |
Stereospecific Linkages in RNA Editing Oligonucleotides
|
|
WO2019233922A1
(en)
|
2018-06-05 |
2019-12-12 |
F. Hoffmann-La Roche Ag |
Oligonucleotides for modulating atxn2 expression
|
|
CA3103429A1
(en)
|
2018-06-14 |
2019-12-19 |
Don W. Cleveland |
Compounds and methods for increasing stmn2 expression
|
|
TWI833770B
(zh)
|
2018-06-27 |
2024-03-01 |
美商Ionis製藥公司 |
用於減少 lrrk2 表現之化合物及方法
|
|
WO2020007700A1
(en)
|
2018-07-02 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting spi1
|
|
WO2020007702A1
(en)
|
2018-07-02 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting bcl2l11
|
|
WO2020007772A1
(en)
|
2018-07-02 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting gbp-1
|
|
SG11202012759XA
(en)
|
2018-07-03 |
2021-01-28 |
Hoffmann La Roche |
Oligonucleotides for modulating tau expression
|
|
WO2020007826A1
(en)
|
2018-07-05 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting mbtps1
|
|
WO2020007889A1
(en)
|
2018-07-05 |
2020-01-09 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting stat1
|
|
WO2020011653A1
(en)
|
2018-07-09 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting kynu
|
|
WO2020011743A1
(en)
|
2018-07-09 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting mafb
|
|
WO2020011869A2
(en)
|
2018-07-11 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting tlr2
|
|
WO2020011744A2
(en)
|
2018-07-11 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting cers5
|
|
WO2020011745A2
(en)
|
2018-07-11 |
2020-01-16 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting cers6
|
|
EP4512407A3
(en)
|
2018-07-13 |
2025-09-24 |
F. Hoffmann-La Roche AG |
Oligonucleotides for modulating rtel1 expression
|
|
EP3823725A4
(en)
|
2018-07-17 |
2023-05-10 |
Aronora, Inc. |
METHODS FOR SAFELY REDUCING THROMBOPOIETIN
|
|
BR112021000308A2
(pt)
|
2018-07-25 |
2021-04-13 |
Ionis Pharmaceuticals, Inc. |
Compostos e métodos para redução da expressão de atxn2
|
|
EP3830101B1
(en)
*
|
2018-07-31 |
2025-11-19 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides comprising a phosphorotrithioate internucleoside linkage
|
|
US20210292358A1
(en)
|
2018-07-31 |
2021-09-23 |
Roche Innovation Center Copenhagen A/S |
Oligonucleotides comprising a phosphorotrithioate internucleoside linkage
|
|
WO2020033899A1
(en)
|
2018-08-10 |
2020-02-13 |
University Of Massachusetts |
Modified oligonucleotides targeting snps
|
|
US11918600B2
(en)
|
2018-08-21 |
2024-03-05 |
Suzhou Ribo Life Science Co., Ltd. |
Nucleic acid, pharmaceutical composition and conjugate containing nucleic acid, and use thereof
|
|
WO2020038973A1
(en)
|
2018-08-23 |
2020-02-27 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting sptlc1
|
|
EP3841220A1
(en)
|
2018-08-23 |
2021-06-30 |
Roche Innovation Center Copenhagen A/S |
Microrna-134 biomarker
|
|
WO2020038971A1
(en)
|
2018-08-23 |
2020-02-27 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting vcan
|
|
WO2020038976A1
(en)
|
2018-08-23 |
2020-02-27 |
Roche Innovation Center Copenhagen A/S |
Antisense oligonucleotides targeting usp8
|
|
JP7627042B2
(ja)
|
2018-08-23 |
2025-02-05 |
ユニバーシティー オブ マサチューセッツ |
Ｏ－メチルリッチ完全安定化オリゴヌクレオチド
|
|
JP2021536239A
(ja)
|
2018-08-28 |
2021-12-27 |
ロシュ イノベーション センター コペンハーゲン エーエス |
スプライス調節化合物を使用したネオアンチゲン操作
|
|
EP3620519A1
(en)
|
2018-09-04 |
2020-03-11 |
F. Hoffmann-La Roche AG |
Use of isolated milk extracellular vesicles for delivering oligonucleotides orally
|
|
US20220056443A1
(en)
*
|
2018-09-06 |
2022-02-24 |
Aptamir Therapeutics, Inc. |
Metabolic benefits of short mir-22 mirna antagomir therapies
|
|
EP3862024A4
(en)
|
2018-09-30 |
2022-08-17 |
Suzhou Ribo Life Science Co., Ltd. |
SIRNA CONJUGATE, METHOD FOR ITS PRODUCTION AND ITS USE
|
|
EP3873920A1
(en)
|
2018-11-01 |
2021-09-08 |
F. Hoffmann-La Roche AG |
Antisense oligonucleotides targeting tia1
|
|
TW202028222A
(zh)
|
2018-11-14 |
2020-08-01 |
美商Ionis製藥公司 |
Foxp3表現之調節劑
|
|
BR112021008967A2
(pt)
|
2018-11-15 |
2021-08-17 |
Ionis Pharmaceuticals, Inc. |
moduladores da expressão de irf5
|
|
SG11202103794QA
(en)
|
2018-11-21 |
2021-05-28 |
Ionis Pharmaceuticals Inc |
Compounds and methods for reducing prion expression
|
|
WO2020117706A1
(en)
|
2018-12-03 |
2020-06-11 |
Triplet Therapeutics, Inc. |
Methods for the treatment of trinucleotide repeat expansion disorders associated with mlh3 activity
|
|
US20220056455A1
(en)
|
2018-12-20 |
2022-02-24 |
Praxis Precision Medicines, Inc. |
Compositions and methods for the treatment of kcnt1 related disorders
|
|
US20220042011A1
(en)
|
2018-12-21 |
2022-02-10 |
Hoffmann-La Roche Inc. |
Antisense oligonucleotides targeting card9
|
|
US12496347B2
(en)
|
2018-12-28 |
2025-12-16 |
Suzhou Ribo Life Science Co., Ltd. |
Nucleic acid, composition and conjugate containing nucleic acid, preparation method therefor and use thereof
|
|
CN113614232A
(zh)
*
|
2019-01-18 |
2021-11-05 |
马萨诸塞大学 |
动态药代动力学修饰锚
|
|
EP3914232A1
(en)
|
2019-01-25 |
2021-12-01 |
F. Hoffmann-La Roche AG |
Lipid vesicle for oral drug delivery
|
|
SG11202107399WA
(en)
|
2019-01-31 |
2021-08-30 |
Ionis Pharmaceuticals Inc |
Modulators of yap1 expression
|
|
CA3130431A1
(en)
*
|
2019-02-20 |
2020-08-27 |
Roche Innovation Center Copenhagen A/S |
Phosphonoacetate gapmer oligonucleotides
|
|
WO2020169696A1
(en)
|
2019-02-20 |
2020-08-27 |
Roche Innovation Center Copenhagen A/S |
Novel phosphoramidites
|
|
CN113474633A
(zh)
|
2019-02-26 |
2021-10-01 |
罗氏创新中心哥本哈根有限公司 |
寡核苷酸配制方法
|
|
TW202540426A
(zh)
|
2019-02-27 |
2025-10-16 |
美商Ionis製藥公司 |
Malat1表現之調節劑
|
|
WO2020178258A1
(en)
*
|
2019-03-05 |
2020-09-10 |
F. Hoffmann-La Roche Ag |
Intracellular targeting of molecules
|
|
FI3947684T3
(fi)
|
2019-03-29 |
2025-05-27 |
Ionis Pharmaceuticals Inc |
Yhdisteitä ja menetelmiä ube3a-ats:n moduloimiseksi
|
|
US20220177894A1
(en)
|
2019-04-02 |
2022-06-09 |
Proqr Therapeutics Ii B.V. |
Antisense oligonucleotides for immunotherapy
|
|
KR20210149107A
(ko)
|
2019-04-03 |
2021-12-08 |
브리스톨-마이어스 스큅 컴퍼니 |
Angptl2 안티센스 올리고뉴클레오티드 및 그의 용도
|
|
US11286485B2
(en)
|
2019-04-04 |
2022-03-29 |
Hoffmann-La Roche Inc. |
Oligonucleotides for modulating ATXN2 expression
|
|
JP7499267B2
(ja)
|
2019-04-04 |
2024-06-13 |
エフ． ホフマン－ラ ロシュ アーゲー |
Ａｔｘｎ２発現を調節するためのオリゴヌクレオチド
|
|
WO2020233680A1
(zh)
|
2019-05-22 |
2020-11-26 |
苏州瑞博生物技术股份有限公司 |
核酸、药物组合物与缀合物及制备方法和用途
|
|
JP7610268B2
(ja)
|
2019-05-22 |
2025-01-08 |
スーチョウ リボ ライフ サイエンス カンパニー、リミテッド |
核酸、薬物組成物及び複合体ならびに調製方法と使用
|
|
AU2020280438B2
(en)
|
2019-05-22 |
2025-03-06 |
Suzhou Ribo Life Science Co., Ltd. |
Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
|
|
EP3978609A4
(en)
|
2019-05-24 |
2024-02-07 |
Suzhou Ribo Life Science Co., Ltd. |
Nucleic acid, pharmaceutical composition, conjugate, preparation method, and use
|
|
CN113905744A
(zh)
|
2019-05-31 |
2022-01-07 |
阿利戈斯治疗公司 |
经修饰的间隙子寡核苷酸及其使用方法
|
|
EP3980539A1
(en)
|
2019-06-06 |
2022-04-13 |
F. Hoffmann-La Roche AG |
Antisense oligonucleotides targeting atxn3
|
|
EP3956450B1
(en)
|
2019-07-26 |
2025-08-13 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating gfap
|
|
AU2020319911A1
(en)
*
|
2019-07-30 |
2022-02-24 |
Mpeg La, L.L.C. |
Subcutaneous delivery of multimeric oligonucleotides with enhanced bioactivity
|
|
MX2022001710A
(es)
|
2019-08-09 |
2022-05-10 |
Univ Massachusetts |
Oligonucleótidos modificados químicamente dirigidos a los snp.
|
|
WO2021049504A1
(ja)
|
2019-09-10 |
2021-03-18 |
第一三共株式会社 |
肝臓送達用ＧａｌＮＡｃ－オリゴヌクレオチドコンジュゲートおよび製造方法
|
|
US12365894B2
(en)
|
2019-09-16 |
2025-07-22 |
University Of Massachusetts |
Branched lipid conjugates of siRNA for specific tissue delivery
|
|
CA3156667A1
(en)
*
|
2019-10-02 |
2021-04-08 |
Sirnaomics, Inc. |
Oligonucleotides with nucleoside analogs
|
|
JP2023506550A
(ja)
|
2019-12-19 |
2023-02-16 |
エフ． ホフマン－ラ ロシュ エージー． |
Ｂ型肝炎ウイルス感染症を処置するためのｓｂｄｓ阻害剤の使用
|
|
JP2023506954A
(ja)
|
2019-12-19 |
2023-02-20 |
エフ． ホフマン－ラ ロシュ エージー． |
Ｂ型肝炎ウイルス感染を処置するためのｓａｒａｆ阻害剤の使用
|
|
US20230020092A1
(en)
*
|
2019-12-19 |
2023-01-19 |
Entrada Therapeutics, Inc. |
Compositions for delivery of antisense compounds
|
|
CN115516091A
(zh)
|
2019-12-19 |
2022-12-23 |
豪夫迈·罗氏有限公司 |
Cops3抑制剂用于治疗乙型肝炎病毒感染的用途
|
|
CN114829599A
(zh)
|
2019-12-19 |
2022-07-29 |
豪夫迈·罗氏有限公司 |
Scamp3抑制剂用于治疗乙型肝炎病毒感染的用途
|
|
CN114901821A
(zh)
*
|
2019-12-19 |
2022-08-12 |
豪夫迈·罗氏有限公司 |
Sept9抑制剂用于治疗乙型肝炎病毒感染的用途
|
|
EP4077672A1
(en)
|
2019-12-20 |
2022-10-26 |
F. Hoffmann-La Roche AG |
Enhanced oligonucleotides for inhibiting scn9a expression
|
|
EP4081639A1
(en)
|
2019-12-24 |
2022-11-02 |
F. Hoffmann-La Roche AG |
Pharmaceutical combination of a therapeutic oligonucleotide targeting hbv and a tlr7 agonist for treatment of hbv
|
|
CN114828852A
(zh)
|
2019-12-24 |
2022-07-29 |
豪夫迈·罗氏有限公司 |
用于治疗hbv的靶向hbv的抗病毒药剂和/或免疫调节剂的药物组合
|
|
EP4097234A1
(en)
|
2020-01-28 |
2022-12-07 |
Université de Strasbourg |
Antisense oligonucleotide targeting linc00518 for treating melanoma
|
|
WO2021158810A1
(en)
|
2020-02-05 |
2021-08-12 |
Bristol-Myers Squibb Company |
Oligonucleotides for splice modulation of camk2d
|
|
CR20220485A
(es)
|
2020-02-28 |
2022-11-10 |
Ionis Pharmaceuticals Inc |
Compuestos y métodos para modular smn2
|
|
EP4110916A1
(en)
|
2020-02-28 |
2023-01-04 |
F. Hoffmann-La Roche AG |
Oligonucleotides for modulating cd73 exon 7 splicing
|
|
KR20230011913A
(ko)
*
|
2020-03-04 |
2023-01-25 |
버브 테라퓨틱스, 인크. |
표적화된 rna 전달을 위한 조성물 및 방법
|
|
US11555190B2
(en)
|
2020-03-19 |
2023-01-17 |
Avidity Biosciences, Inc. |
Compositions and methods of treating Facioscapulohumeral muscular dystrophy
|
|
AU2021260934A1
(en)
*
|
2020-04-21 |
2022-11-24 |
Flagship Pioneering, Inc. |
Bifunctional molecules and methods of using thereof
|
|
MX2022013707A
(es)
|
2020-05-01 |
2022-12-07 |
Ionis Pharmaceuticals Inc |
Compuestos y metodos para modular atxn1.
|
|
JP2023527693A
(ja)
|
2020-05-11 |
2023-06-30 |
ジェネンテック， インコーポレイテッド |
神経疾患を治療するための補体成分ｃ１ｒ阻害剤、並びに関連する組成物、システム、及びそれを使用する方法
|
|
WO2021231204A1
(en)
|
2020-05-11 |
2021-11-18 |
Genentech, Inc. |
Complement component 4 inhibitors for treating neurological diseases, and related compositons, systems and methods of using same
|
|
CN115551519A
(zh)
|
2020-05-11 |
2022-12-30 |
基因泰克公司 |
用于治疗神经系统疾病的补体组分c1s抑制剂以及相关的组合物、系统和使用它们的方法
|
|
TW202208628A
(zh)
|
2020-05-13 |
2022-03-01 |
瑞士商赫孚孟拉羅股份公司 |
靶向顆粒蛋白前體之寡核苷酸促效劑
|
|
WO2021231679A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of gap junction protein beta 2 (gjb2)
|
|
WO2021231675A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of argininosuccinate synthetase (ass1)
|
|
WO2021231692A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of otoferlin (otof)
|
|
EP4150089A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of retinoschisin 1 (rs1)
|
|
WO2021231685A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of transmembrane channel-like protein 1 (tmc1)
|
|
EP4150078A1
(en)
|
2020-05-15 |
2023-03-22 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of argininosuccinate lyase (asl)
|
|
WO2021231673A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of leucine rich repeat kinase 2 (lrrk2)
|
|
WO2021231680A1
(en)
|
2020-05-15 |
2021-11-18 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of methyl-cpg binding protein 2 (mecp2)
|
|
CN115884777A
(zh)
|
2020-05-22 |
2023-03-31 |
豪夫迈·罗氏有限公司 |
用于card9的剪接调节的寡核苷酸
|
|
WO2021242883A1
(en)
|
2020-05-26 |
2021-12-02 |
University Of Massachusetts |
Synthetic oligonucleotides having regions of block and cluster modifications
|
|
AR122534A1
(es)
|
2020-06-03 |
2022-09-21 |
Triplet Therapeutics Inc |
Métodos para el tratamiento de los trastornos de expansión por repetición de nucleótidos asociados con la actividad de msh3
|
|
US20230212572A1
(en)
|
2020-06-09 |
2023-07-06 |
Roche Innovation Center Copenhagen A/S |
Guanosine Analogues for Use in Therapeutics Polynucleotides
|
|
AR122731A1
(es)
|
2020-06-26 |
2022-10-05 |
Hoffmann La Roche |
Oligonucleótidos mejorados para modular la expresión de fubp1
|
|
BR112022024206A2
(pt)
|
2020-06-29 |
2023-01-03 |
Ionis Pharmaceuticals Inc |
Compostos e métodos para modular plp1
|
|
WO2022018187A1
(en)
|
2020-07-23 |
2022-01-27 |
F. Hoffmann-La Roche Ag |
Oligonucleotides targeting rna binding protein sites
|
|
WO2022018155A1
(en)
|
2020-07-23 |
2022-01-27 |
F. Hoffmann-La Roche Ag |
Lna oligonucleotides for splice modulation of stmn2
|
|
AU2021315992A1
(en)
|
2020-07-28 |
2023-02-09 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for reducing app expression
|
|
CN111671913B
(zh)
*
|
2020-07-30 |
2022-02-08 |
四川大学 |
一种量子点-小核酸偶联物及其用途
|
|
IL300258A
(en)
|
2020-08-07 |
2023-03-01 |
Ionis Pharmaceuticals Inc |
Compounds and methods for modulating SCN2A
|
|
JP2023538630A
(ja)
|
2020-08-21 |
2023-09-08 |
エフ． ホフマン－ラ ロシュ アーゲー |
Ｂ型肝炎ウイルス感染症を処置するためのａ１ｃｆ阻害剤の使用
|
|
WO2022072950A1
(en)
*
|
2020-10-02 |
2022-04-07 |
Sirnaomics, Inc. |
NUCLEOSIDE CONTAINING siRNAS FOR TREAT VIRAL DISEASES
|
|
EP4136092B1
(en)
|
2020-11-18 |
2024-07-31 |
Ionis Pharmaceuticals, Inc. |
Compounds and methods for modulating angiotensinogen expression
|
|
WO2022117747A2
(en)
|
2020-12-03 |
2022-06-09 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides targeting atxn3
|
|
TW202237842A
(zh)
|
2020-12-03 |
2022-10-01 |
瑞士商赫孚孟拉羅股份公司 |
靶向ａｔｘｎ３之反義寡核苷酸
|
|
TW202229553A
(zh)
|
2020-12-18 |
2022-08-01 |
瑞士商赫孚孟拉羅股份公司 |
靶向顆粒蛋白前體之反義寡核苷酸
|
|
JP2023554346A
(ja)
|
2020-12-18 |
2023-12-27 |
アイオーニス ファーマシューティカルズ， インコーポレーテッド |
第ｘｉｉ因子を調節するための化合物及び方法
|
|
WO2022136140A1
(en)
|
2020-12-22 |
2022-06-30 |
F. Hoffmann-La Roche Ag |
Oligonucleotides targeting xbp1
|
|
CN114716518A
(zh)
*
|
2021-01-06 |
2022-07-08 |
圣诺制药公司 |
一种能够抑制pcsk9表达的分子构造及药物组合物
|
|
US20240083990A1
(en)
|
2021-01-26 |
2024-03-14 |
Universite Brest Bretagne Occidentale |
Novel stim1 splicing variants and uses thereof
|
|
TW202246500A
(zh)
|
2021-02-02 |
2022-12-01 |
瑞士商赫孚孟拉羅股份公司 |
用於抑制 ｒｔｅｌ１ 表現之增強型寡核苷酸
|
|
PE20240696A1
(es)
|
2021-03-08 |
2024-04-10 |
Servier Lab |
Oligonucleotidos antisentido para inhibir la expresion de la alfa-sinucleina
|
|
WO2022232650A1
(en)
*
|
2021-04-30 |
2022-11-03 |
Ionis Pharmaceuticals, Inc. |
Methods for reducing agt expression
|
|
EP4341405A1
(en)
|
2021-05-20 |
2024-03-27 |
Korro Bio, Inc. |
Methods and compositions for adar-mediated editing
|
|
WO2022256283A2
(en)
|
2021-06-01 |
2022-12-08 |
Korro Bio, Inc. |
Methods for restoring protein function using adar
|
|
KR20240019228A
(ko)
|
2021-06-08 |
2024-02-14 |
에프. 호프만-라 로슈 아게 |
올리고뉴클레오티드 프로그래눌린 효현제
|
|
US12378267B2
(en)
|
2021-06-17 |
2025-08-05 |
Entrada Therapeutics, Inc. |
Synthesis of FMOC-protected morpholino monomers and oligomers
|
|
KR20240023602A
(ko)
|
2021-06-18 |
2024-02-22 |
아이오니스 파마수티컬즈, 인코포레이티드 |
Ifnar1 발현을 감소시키기 위한 화합물 및 방법
|
|
AU2022299169A1
(en)
|
2021-06-23 |
2024-02-08 |
Beth Israel Deaconess Medical Center, Inc. |
Optimized anti-flt1 oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders
|
|
US20230194709A9
(en)
|
2021-06-29 |
2023-06-22 |
Seagate Technology Llc |
Range information detection using coherent pulse sets with selected waveform characteristics
|
|
WO2023278410A1
(en)
|
2021-06-29 |
2023-01-05 |
Korro Bio, Inc. |
Methods and compositions for adar-mediated editing
|
|
JP2024530647A
(ja)
|
2021-08-03 |
2024-08-23 |
ヴァーヴ・セラピューティクス，インコーポレーテッド |
標的ｒｎａ送達のための組成物および方法
|
|
US20250188455A1
(en)
*
|
2021-09-02 |
2025-06-12 |
Vanderbilt University |
Lipophilic oligonucleotide conjugates
|
|
MX2024003266A
(es)
|
2021-09-16 |
2024-04-03 |
Avidity Biosciences Inc |
Composiciones y metodos de tratamiento de la distrofia muscular facioescapulohumeral.
|
|
US20250352667A1
(en)
|
2021-10-22 |
2025-11-20 |
Korro Bio, Inc. |
Methods and compositions for disrupting nrf2-keap1 protein interaction by adar mediated rna editing
|
|
EP4426833A1
(en)
|
2021-11-03 |
2024-09-11 |
F. Hoffmann-La Roche AG |
Oligonucleotides for modulating apolipoprotein e4 expression
|
|
CA3234478A1
(en)
|
2021-11-11 |
2023-05-19 |
Souphalone LUANGSAY |
Pharmaceutical combinations for treatment of hbv
|
|
WO2023102188A1
(en)
*
|
2021-12-03 |
2023-06-08 |
Quralis Corporation |
Gapmer antisense oligonucleotides with modified backbone chemistries
|
|
EP4444882A1
(en)
|
2021-12-07 |
2024-10-16 |
F. Hoffmann-La Roche AG |
Antisense oligonucleotides targeting actl6b
|
|
EP4448763A1
(en)
|
2021-12-17 |
2024-10-23 |
F. Hoffmann-La Roche AG |
Oligonucleotide gba agonists
|
|
EP4448106A1
(en)
|
2021-12-17 |
2024-10-23 |
Hoffmann-La Roche Inc. |
Combination of oligonucleotides for modulating rtel1 and fubp1
|
|
JP2024547071A
(ja)
|
2021-12-20 |
2024-12-26 |
エフ． ホフマン－ラ ロシュ アーゲー |
トレオース核酸アンチセンスオリゴヌクレオチドおよびその方法
|
|
EP4465994A1
(en)
|
2022-01-20 |
2024-11-27 |
Genentech, Inc. |
Antisense oligonucleotides for modulating tmem106b expression
|
|
US20240167040A1
(en)
|
2022-02-21 |
2024-05-23 |
Hoffmann-La Roche Inc. |
Antisense oligonucleotide
|
|
KR20240161967A
(ko)
|
2022-03-16 |
2024-11-13 |
다이이찌 산쿄 가부시키가이샤 |
트랜스페린 수용체 2 의 발현을 억제하는 siRNA
|
|
JPWO2023176863A1
(https=)
|
2022-03-16 |
2023-09-21 |
|
|
|
CN119173632A
(zh)
|
2022-05-10 |
2024-12-20 |
豪夫迈·罗氏有限公司 |
靶向cfp-elk1基因间区域的反义寡核苷酸
|
|
PE20250394A1
(es)
|
2022-05-18 |
2025-02-11 |
Hoffmann La Roche |
Oligonucleotidos mejorados que actuan sobre sitios de proteina de union a arn
|
|
EP4282964A1
(en)
*
|
2022-05-23 |
2023-11-29 |
Universitat de Valéncia |
Oligonucleotides conjugated to oleic acid and uses thereof
|
|
CN119365600A
(zh)
|
2022-06-17 |
2025-01-24 |
豪夫迈·罗氏有限公司 |
靶向颗粒蛋白前体的反义寡核苷酸
|
|
EP4332221A1
(en)
|
2022-08-29 |
2024-03-06 |
Roche Innovation Center Copenhagen A/S |
Threose nucleic acid antisense oligonucleotides and methods thereof
|
|
WO2024052403A1
(en)
|
2022-09-06 |
2024-03-14 |
F. Hoffmann-La Roche Ag |
Double-stranded rna molecule for administration to the eye
|
|
JP2025532127A
(ja)
|
2022-09-23 |
2025-09-29 |
アイオーニス ファーマシューティカルズ， インコーポレーテッド |
Ｍｅｃｐ２発現を低減する化合物及び方法
|
|
IL321025A
(en)
*
|
2022-11-21 |
2025-07-01 |
Pepgen Inc |
Cell-penetrating peptides, conjugates thereof, and methods of their use
|
|
WO2024126654A1
(en)
|
2022-12-14 |
2024-06-20 |
F. Hoffmann-La Roche Ag |
Antisense oligonucleotides targeting actl6b
|
|
WO2024153586A1
(en)
|
2023-01-16 |
2024-07-25 |
Institut National De Recherche Pour L'agriculture, L'alimentation Et L'environnement |
Antisense molecules and their uses for the treatment of coronavirus infection, in particular the treatment of covid-19 related to sars-cov-2 infection
|
|
JP2026504911A
(ja)
|
2023-01-19 |
2026-02-10 |
アルトス ラブス，インコーポレーテッド |
臓器移植における再生因子の使用
|
|
WO2024196893A1
(en)
*
|
2023-03-17 |
2024-09-26 |
Camford Labs Inc. |
Chemically modified nucleotides
|
|
EP4689116A1
(en)
*
|
2023-03-30 |
2026-02-11 |
Ractigen Therapeutics |
Vehicles for delivering oligonucleotides and methods of use thereof
|
|
CN121263524A
(zh)
|
2023-05-04 |
2026-01-02 |
豪夫迈·罗氏有限公司 |
能够上调葡糖脑苷脂酶表达的寡核苷酸
|
|
TW202508607A
(zh)
*
|
2023-05-19 |
2025-03-01 |
大陸商北京炫景瑞醫藥科技有限公司 |
雙股寡核苷酸及其共軛物和用途
|
|
TW202516004A
(zh)
|
2023-06-16 |
2025-04-16 |
瑞士商赫孚孟拉羅股份公司 |
調節ｊａｋ１表現之雙股寡核苷酸
|
|
WO2025036916A1
(en)
|
2023-08-16 |
2025-02-20 |
Les Laboratoires Servier |
Oligonucleotides for modulating kcnt1 expression
|
|
WO2026006436A1
(en)
|
2024-06-25 |
2026-01-02 |
Korro Bio, Inc. |
Methods and compositions for the adar-mediated editing of tar dna binding protein 43 kda (tdp43)
|
|
WO2026024954A2
(en)
|
2024-07-24 |
2026-01-29 |
Altos Labs, Inc. |
Use of regeneration factors in organ transplantation
|
|
EP4711455A1
(en)
|
2024-09-11 |
2026-03-18 |
Aarhus Universitet |
Small artificial rna (smartrna) oligonucleotide for modulating protein expression
|